Thelansis’s "Platinum-Resistant Recurrent Ovarian Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Platinum-Resistant Recurrent Ovarian Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Platinum-resistant recurrent ovarian cancer (PROC) is epithelial ovarian, fallopian tube, or primary peritoneal cancer that progresses during platinum therapy or recurs within six months of its completion. Disease may spread across the peritoneum and cause ascites, abdominal discomfort, bloating, bowel symptoms, fatigue, or weight loss. Treatment is individualized by tumor subtype, prior regimens, fitness, and biomarkers. Options include paclitaxel, pegylated liposomal doxorubicin, topotecan, or gemcitabine, sometimes with bevacizumab. For tumors with high folate receptor alpha (FRα) expression, mirvetuximab soravtansine is a biomarker-selected antibody-drug conjugate. In the United States, relacorilant plus nab-paclitaxel was approved in March 2026 for eligible patients previously treated with bevacizumab. Responses may be brief, and cumulative toxicity remains a challenge, sustaining the need for better-tolerated, biomarker-guided therapies.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
1. Key Findings and Analyst Commentary
2. Disease Context
3. Epidemiology
4. Market Size and Forecast
5. Competitive Landscape
6. Unmet Need and TPP Analysis
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Platinum-Resistant Recurrent Ovarian Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036 report
Our team will get in touch with you shortly about the Platinum-Resistant Recurrent Ovarian Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036 report.